Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
Rhea-AI Summary
Erasca (Nasdaq: ERAS) reported Q4 and full-year 2025 results and business updates on March 12, 2026. The company highlighted promising early Phase 1 activity for ERAS-0015, planned H1 2026 monotherapy data for ERAS-0015 and H2 2026 data for ERAS-4001, a $258.8M upsized financing, and $341.8M cash at 12/31/2025.
Management expects pro forma cash of $434M to fund operations into H2 2028; issued U.S. composition patents protect ERAS-0015 and ERAS-4001 through 2043.
Positive
- ERAS-0015 early confirmed partial responses across multiple RAS-mutant tumors
- Completed upsized public offering raising approximately $258.8M gross proceeds
- Pro forma cash position of $434M expected to fund operations into H2 2028
- U.S. composition patents issued protecting ERAS-0015 and ERAS-4001 through 2043
Negative
- Cash, cash equivalents, and marketable securities declined to $341.8M as of 12/31/2025
- Full-year net loss of $124.5M for 2025 (vs $161.7M in 2024) indicating continued cash burn
- In-process R&D charges of $9.5M in 2025 related to license milestones
News Market Reaction – ERAS
In the Mar 13 session, ERAS declined 7.03%, reflecting a notable negative market reaction. Argus tracked a peak move of +7.1% during that session. Argus tracked a trough of -6.6% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Q3 2025 earnings | Positive | -4.2% | Q3 2025 results, ERAS-0015 patent and pipeline timing, cash runway to H2 2028. |
| Aug 12 | Q2 2025 earnings | Positive | +3.9% | Q2 2025 results, dual IND clearances and strong cash supporting H2 2028 runway. |
| May 13 | Q1 2025 earnings | Positive | -4.5% | Q1 2025 update with FDA clearance/IND progress and extended H2 2028 runway. |
| Mar 20 | FY/Q4 2024 earnings | Positive | +3.4% | FY 2024 results, strong cash of $440.5M and advancement of RAS programs. |
| Nov 12 | Q3 2024 earnings | Positive | -4.7% | Q3 2024 results with positive SEACRAFT-1 data and solid cash position. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings updates have often seen choppy reactions, with a slight historical bias toward modest declines despite generally constructive clinical and cash runway commentary.
Over the last five earnings releases from Nov 2024 through Nov 2025, Erasca consistently highlighted advancement of its RAS-targeting pipeline (ERAS-0015 and ERAS-4001) and maintained a substantial cash runway into H2 2027–2028. Net losses and R&D spend have generally trended lower year-over-year. Market reactions have been mixed, with both rallies and selloffs, suggesting investors reassess valuation each quarter even when the operational story and cash outlook remain stable, providing useful context for today’s full-year 2025 update.
Key Terms
pharmacokinetics medical
monotherapy medical
dose escalation medical
dose-limiting toxicities medical
adverse events medical
composition of matter regulatory
Phase 1 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics
Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026
Successfully completed
Robust balance sheet with pro forma cash, cash equivalents, and marketable securities of
SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter and full year ended December 31, 2025.
“Our RAS-targeting franchise continues to advance rapidly in the clinic, reflecting our strong operational execution and high investigator and patient enthusiasm,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Importantly, the best-in-class potential of our pan-RAS molecular glue ERAS-0015 was underscored by ongoing partial responses at a low dose of 8 mg QD across multiple tumor types and RAS mutations, together with favorable safety and pharmacokinetics (PK) data, as of the data cutoff*. This clinical progress and the successful upsized public offering heighten excitement in our RAS-targeting franchise and strengthen our financial position as we further advance clinical development.”
Dr. Lim continued, “In 2026, we expect additional Phase 1 data for ERAS-0015 in the first half of the year, as well as initial data for our pan-KRAS inhibitor ERAS-4001 in the second half of the year. Our focus continues to be on streamlined execution across our clinical programs, and with our recent capital infusion, we believe that we are strongly positioned to drive our RAS-targeting franchise for the benefit of patients.”
Research and Development (R&D) Highlights
- Announced Promising Early Clinical Data for ERAS-0015: In January 2026, Erasca announced promising early clinical activity for ERAS-0015 during dose escalation, including confirmed partial responses in multiple tumor types with different RAS mutations, favorable safety and tolerability data, with no dose-limiting toxicities and predominantly low-grade adverse events and encouraging safety and well-behaved, linear PK.*
* Data cutoff date was January 7, 2026
Corporate Highlights
- Expanded License Agreement Territory for ERAS-0015: In March 2026, Erasca announced the expansion of its existing licensing agreement with Joyo Pharmatech Co., Ltd. (Joyo) to include China, Hong Kong, and Macau, providing Erasca with worldwide rights to its potential best-in-class pan-RAS molecular glue ERAS-0015.
- Completed Upsized Financing: In January 2026, Erasca completed a successful upsized public offering, raising approximately
$258.8 million in gross proceeds. The transaction, supported by new and existing healthcare-focused investors, significantly strengthened Erasca’s balance sheet. - Composition of Matter Patents Issued in the U.S. for RAS-Targeting Franchise: Erasca announced that the U.S. Patent and Trademark Office issued patents for its RAS-Targeting Franchise
- U.S. patent No. 12,552,813 titled “Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof,” was issued in February 2026, which protects the composition of matter of ERAS-4001 and related compositions until June 2043, which period may be subject to patent term adjustments or extensions
- U.S. patent No. 12,458,647 titled “Macrocyclic Derivative And Use Thereof,” was issued in October 2025, which protects the composition of matter of ERAS-0015 and related compositions until September 2043, which period may be subject to patent term adjustments or extensions
Key Upcoming Milestones
- AURORAS-1 and JYP0015M101**: Phase 1 trials for ERAS-0015 (pan-RAS molecular glue) in patients with RAS-mutant solid tumors in the US and China, respectively
- Phase 1 monotherapy data from both the US and China expected in the first half of 2026
- Initiation of AURORAS-1 monotherapy expansion cohorts and combination dose escalation cohort planned for the second half of 2026
- AURORAS-1 monotherapy expansion data and combination dose escalation data planned for 2027
- BOREALIS-1: Phase 1 trial for ERAS-4001 (pan-KRAS inhibitor) in patients with KRAS-mutant solid tumors
- Phase 1 monotherapy data expected in the second half of 2026
- Initiation of monotherapy expansion cohorts and combination dose escalation cohorts planned for 2027
** JYP0015M101 is a clinical trial in China sponsored by Joyo that is assessing ERAS-0015 in adult patients with advanced solid tumors harboring specific RAS mutations.
Fourth Quarter and Full Year 2025 Financial Results
Cash Position: Cash, cash equivalents, and marketable securities were
Research and Development (R&D) Expenses: R&D expenses were
General and Administrative (G&A) Expenses: G&A expenses were
Net Loss: Net loss was
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Cautionary Note Regarding Forward-Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the potential therapeutic benefits of our product candidates, including ERAS-0015 and ERAS-4001, and the planned advancement of our development pipeline, including the anticipated timing of data readouts for the AURORAS-1 and JYP0015M101 trials, and the BOREALIS-1 trial, and the anticipated timing of the initiation of additional expansion cohorts for the AURORAS-1 and BOREALIS-1 trials; our belief that we are strongly positioned to drive our RAS-targeting franchise for the benefit of patients; the sufficiency of our cash, cash equivalents, and marketable securities to fund our operations into the second half of 2028; and statements relating to the protections provided by our intellectual property portfolio, including the issuance of patents, the anticipated periods of time until such patents expire, and the related implications for us. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our approach to the discovery and development of product candidates based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; preliminary results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including the risk that an unconfirmed partial response to treatment may not ultimately result in a confirmed partial response to treatment after follow-up evaluations; any forward-looking statements regarding dose-response relationships reflect current expectations and/or assumptions, and are subject to risks and uncertainties that could cause actual results to differ materially; our assumptions about the development potential of ERAS-0015 and ERAS-4001 are based in large part on the preclinical data generated by the licensors and we may observe materially and adversely different results as we conduct our planned studies and trials; the initial data presented from the JYP0015M101 trial will be based upon data generated by the licensor; results from preclinical studies or early clinical trials not necessarily being predictive of future results; our assumptions around which programs may have a higher probability of success may not be accurate, and we may expend our limited resources to pursue a particular product candidate and/or indication and fail to capitalize on product candidates or indications with greater development or commercial potential; potential delays in the commencement, enrollment, data readout, and completion of clinical trials and preclinical studies; our dependence on third parties in connection with manufacturing, research, and preclinical and clinical testing; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims; unfavorable results from preclinical studies or clinical trials; the inability to realize any benefits from our current licenses, acquisitions, and collaborations, and any future licenses, acquisitions, or collaborations, and our ability to fulfill our obligations under such arrangements; regulatory developments in the United States and foreign countries; our ability to obtain and maintain intellectual property protection for our product candidates and maintain our rights under intellectual property licenses; our ability to fund our operating plans with our current cash, cash equivalents, and marketable securities; we may use our capital resources sooner than we expect; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Erasca, Inc.
Selected Consolidated Balance Sheet Data
(In thousands)
(Unaudited)
| December 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Balance Sheet Data: | ||||||||
| Cash, cash equivalents, and marketable securities | $ | 341,796 | $ | 440,473 | ||||
| Working capital | 257,728 | 277,398 | ||||||
| Total assets | 396,154 | 502,526 | ||||||
| Accumulated deficit | (892,209) | (767,663) | ||||||
| Total stockholders’ equity | 325,171 | 423,499 | ||||||
Erasca, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 23,241 | $ | 26,122 | $ | 92,854 | $ | 115,359 | ||||||||
| In-process research and development | — | — | 9,500 | 22,500 | ||||||||||||
| General and administrative | 9,363 | 9,590 | 38,551 | 41,728 | ||||||||||||
| Total operating expenses | 32,604 | 35,712 | 140,905 | 179,587 | ||||||||||||
| Loss from operations | (32,604) | (35,712) | (140,905) | (179,587) | ||||||||||||
| Other income (expense) | ||||||||||||||||
| Interest income | 3,566 | 5,283 | 16,607 | 20,093 | ||||||||||||
| Other expense, net | (54) | (1,803) | (248) | (2,156) | ||||||||||||
| Total other income (expense), net | 3,512 | 3,480 | 16,359 | 17,937 | ||||||||||||
| Net loss | $ | (29,092) | $ | (32,232) | $ | (124,546) | $ | (161,650) | ||||||||
| Net loss per share, basic and diluted | $ | (0.10) | $ | (0.11) | $ | (0.44) | $ | (0.69) | ||||||||
| Weighted-average shares of common stock used in computing net loss per share, basic and diluted | 283,829,318 | 282,845,918 | 283,533,696 | 233,817,916 | ||||||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Unrealized (loss) gain on marketable securities, net | (21) | (1,420) | 223 | 328 | ||||||||||||
| Comprehensive loss | $ | (29,113) | $ | (33,652) | $ | (124,323) | $ | (161,322) | ||||||||
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
